Jean-Pierre Lindenmayer, MD

  • 35Articles
  • 160.5KReads
  • 1998–2022Active
  • 104Collaborators
  • 3.9KCitations

About

Jean-Pierre Lindenmayer, MD, is affiliated with the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York. Lindenmayer has contributed 35 articles to Psychiatrist.com between 1998 and 2022, focusing on topics including schizophrenia, metabolic disorders, psychiatry, violence and aggression, dementia, depression, neurology, and weight. Frequent collaborators include Charles H. Hennekens, Dan W. Haupt, Daniel E. Casey, David C. Henderson, and Harold E. Lebovitz.

Publications

JCP
Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia
Original Research

Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia

April 11, 2022

This clinical trial investigated whether hospitalization rates improved when patients with schizophrenia were treated via a digital medicine system (aripiprazole tablets with sensor) versus oral standard-of-care therapy.
, , , et al
JCP
Consensus Statement

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
Commentary

Treatment-Resistant Schizophrenia Guideline

March 5, 2019

Read expert commentary on guidelines for treatment-resistant schizophrenia (TRS) to make more informed treatment decisions.
, , , et al
JCP
Original Research

Antipsychotic Therapy in Schizophrenia

April 14, 2015

Read a study discussing Real-World Outcomes of Paliperidone Palmitate compared to Daily Oral Antipsychotic Therapy in Schizophrenia.
, , , et al
JCP
Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

, , , et al
JCP
Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

, , , et al
JCP
Original Research

Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

October 6, 2009

, , , et al
JCP
Original Research

Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness

September 22, 2009

, , , et al
JCP
Original Research

Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response

June 2, 2009

, , , et al
JCP
Letter to the Editor

Aripiprazole-Induced Agitation After Clozapine Discontinuation: A Case Report

May 15, 2009

,
JCP
Article

Modafinil as an Adjunctive Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia: A Critical Review

November 18, 2008

, , , et al
JCP
Letter to the Editor

Efficacy of Molindone in Treatment-Refractory Agitated Schizophrenia: Three Case Reports

June 30, 2008

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe